These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15992660)

  • 1. Treatment order in managing systolic ventricular dysfunction.
    MacFadyen RJ; Davis R
    J Am Coll Cardiol; 2005 Jul; 46(1):182-3; author reply 183. PubMed ID: 15992660
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
    Scott RL
    Cardiol Clin; 2008 Feb; 26(1):73-7, vii. PubMed ID: 18312907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed recovery of left ventricular systolic dysfunction: ''give time to medical therapy''.
    Ennezat PV; Gonin X; Darchis J; De Groote P; Lamblin N; Bauters C; Lejemtel T; Asseman P
    Minerva Cardioangiol; 2007 Jun; 55(3):426-7. PubMed ID: 17534261
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing patients with heart failure: the reality of clinical practice.
    Squire I
    Eur Heart J; 2005 Dec; 26(24):2611-3. PubMed ID: 16219652
    [No Abstract]   [Full Text] [Related]  

  • 5. [Asymptomatic left ventricular systolic dysfunction].
    Kupari M
    Duodecim; 1997; 113(10):893, 895, 897. PubMed ID: 11466823
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.
    Roy P; Bouchard J; Amyot R; Madore F
    Am J Kidney Dis; 2006 Oct; 48(4):645-51. PubMed ID: 16997061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?
    Fang JC
    Circulation; 2005 Oct; 112(16):2380-2. PubMed ID: 16230494
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
    Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of neurohormonal modulators in heart failure with relatively preserved systolic function.
    Rapp JA; Gheorghiade M
    Cardiol Clin; 2008 Feb; 26(1):23-40, vi. PubMed ID: 18312903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT; Greenberg BH; Yancy CW
    Am J Cardiol; 2008 Sep; 102(5A):21G-28G. PubMed ID: 18722188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Finely adjusted differential therapy succeeds this way! References for dose adjustments in heart failure (interview by Dr. Dirk Einecke)].
    Erdmann E
    MMW Fortschr Med; 2005 Sep; 147(39):11. PubMed ID: 16245770
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chronic left heart failure. A focus on the pathogenetic basis of medical treatment].
    Novosel MK; Haghfelt TH
    Ugeskr Laeger; 2006 May; 168(19):1854-6. PubMed ID: 16756801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
    Houpe D; Peltier M; Cohen-Solal A; Béguin M; Lévy F; Slama M; Chapelain K; Tribouilloy C
    Int J Cardiol; 2005 Sep; 103(3):286-92. PubMed ID: 16098391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial.
    Ahn SA; Jong P; Yusuf S; Bangdiwala SI; Pouleur HG; Rousseau MF
    J Am Coll Cardiol; 2006 May; 47(9):1904-5. PubMed ID: 16682319
    [No Abstract]   [Full Text] [Related]  

  • 15. I have been diagnosed with a poor ejection fraction from my left ventricle. What does that mean, and what medications would be most beneficial?
    Health News; 2006 Feb; 12(2):16. PubMed ID: 16453941
    [No Abstract]   [Full Text] [Related]  

  • 16. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive adrenergic blockade post myocardial infarction left ventricular dysfunction.
    Fonarow GC
    Cardiol Clin; 2008 Feb; 26(1):79-89, vii. PubMed ID: 18312908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study.
    Peltier M; Houpe D; Cohen-Solal A; Béguin M; Levy F; Tribouilloy C
    Int J Cardiol; 2007 Jun; 118(3):363-9. PubMed ID: 17049391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors.
    Ascenção R; Fortuna P; Reis I; Carneiro AV
    Rev Port Cardiol; 2008 Sep; 27(9):1169-87. PubMed ID: 19044179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life.
    Giglio V
    Am J Cardiol; 2007 Jan; 99(1):147-8. PubMed ID: 17196482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.